Navigation Links
FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Date:4/6/2012

INDIANAPOLIS, April 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.[1] Amyvid binds to amyloid plaques, a hallmark characteristic of Alzheimer's Disease,[2],[3],[4] and is detected using PET scan images of the brain.[1]

A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer's Disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's Disease.[2] [5] A positive Amyvid scan indicates moderate to frequent amyloid plaques are present; this amount of amyloid plaque is present in patients with Alzheimer's Disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.[1], [4], [6]

It's important to note that Amyvid is an adjunct to other diagnostic evaluations. A positive Amyvid scan does not establish a diagnosis of Alzheimer's Disease, or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or monitoring responses to therapies.[1]

Alzheimer's Disease is one of several possible causes of cognitive decline. Alzheimer's Disease and other causes of cognitive impairment share many overlapping symptoms including memory, visuospatial ability, executive function, behavior and language deficiencies.[4],[7] Because a definitive diagnosis of Alzheimer's Disease is usually determined u
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB)
2. FDA Approves Additional Manufacturer of Methoxsalen
3. FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
4. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
5. FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer
6. FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
7. ASAM Approves Prescription Drug Policy
8. FDA Approves Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
9. FDA Approves Shared REMS (Risk Evaluation and Mitigation Strategy) Program for all TIRF (Transmucosal Immediate Release Fentanyl) Pain Treatments
10. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
11. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
(Date:7/11/2014)... 12, 2014 According to new ... market is expected to register a CAGR of ... Browse 71 market data tables and 76 figures ... "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market analysis ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- People with the lowest ... called peripheral artery disease (PAD), a new study suggests. ... blood to the limbs, most often the legs. The condition ... of the arteries throughout the body. People with PAD have ... analyzed data from nearly 6,800 people with PAD who took ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... , , , ... females, a team of Ohio physicians representing the Women,s Dermatologic ... safety education for tennis fans enjoying the Western & Southern ... Saturday, August 15, from 9:00 a.m.-5:00 p.m. Led by board-certified dermatologist ...
... 10 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, ... multi-year distribution,agreements for China with Biotest AG and Cutera ... in Dreieich, Germany (SDAX: BIO3), specializes in,innovative hematology and ...
... , , ANN ARBOR, Mich., ... U.S. health systems based on their hospitals, clinical performance. They are: , , ... , Catholic Healthcare Partners -- Cincinnati, OH , ... HealthEast Care System -- Saint Paul, MN , Henry ...
... PHILADELPHIA, Pennsylvania, August 10 , ... Improve Patient Care, Help,Prevent Costly Mistakes; Hospitals Benefit From ... a world leader in healthcare and medical publishing and ... tool within,Mosby,s Nursing Consult designed to help nurses prevent ...
... ... Enhances Innovative Solutions for Travelers and Individuals , ... Indianapolis, IN (PRWEB) August 10, 2009 ... insurance, today announced it has signed an agreement with Eldorado Computing, Inc. (Eldorado) ...
... ... balance, confidence and quality of life. , ... Hamilton, AL (PRWEB) Jeanne Crace, 70, who has five daughters, ... Parkinson,s disease. , , , , ,Parkinson,s Disease remains a mystery of medical ...
Cached Medicine News:Health News:Ohio Dermatologists to Help Tennis Community Get Into the Swing of Sun Safety 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 4Health News:Thomson Reuters Research Identifies Top U.S. Health Systems 2Health News:Thomson Reuters Research Identifies Top U.S. Health Systems 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 2Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 4Health News:HCC Medical Insurance Services Selects Eldorado's Innovative Claims & Benefits Platform 2Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 2Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 3
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Symbol 10' Test Chart 10/100 to 10/10 size. 9" x 14"....
Wilbrandt-binkhorst irrigating cannula....
Binkhorst, length 35 mm....
Medicine Products: